Health
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
Indivior PLC (Nasdaq: INDV) presented three new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week, showcasing real-world evidence on the clinical and economic impact of monthly injectable buprenorphine in the treatment of OUD. The data highlights the potential of SUBLOCADE to improve patient outcomes while reducing healthcare resource utilization across both Medicaid and commercially insured populations.
About this update from Indivior Pharmaceuticals, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization","length":192,"tagName":"p"}]},{"val":[{"type":"text","content":"Adherence to SUBLOCADE was associated with lower rates of infectious disease complications and improved chronic disease management in people with opioid use disorder (OUD)","length":256,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":448,"olType":false},{"type":"text","content":"RICHMOND, Va., Nov. 3, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented three new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week, showcasing real-world evidence on the clinical and economic impact of monthly injectable buprenorphine in the treatment of OUD. The data highlights the potential of SUBLOCADE to improve patient outcomes while reducing healthcare resource utilization across both Medicaid and commercially insured populations.","length":524,"tagName":"p"},{"type":"image","alt":"Indivior (PRNewsfoto/Indivior)","displaySize":"","headline":null,"caption":"Indivior (PRNewsfoto/Indivior)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":130,"url":"https://media.zenfs.com/en/prnewswire.com/e9a6eb17aaf44dddfab6f7d13d2315b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.uJSnzZQQuSzYp3kZpAAsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e9a6eb17aaf44dddfab6f7d13d2315b7","width":400,"height":130}},"href":"https://mma.prnewswire.com/media/1814851/Indivior_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""These new findings reinforce what key stakeholders have long sought: treatment that delivers both better outcomes for patients and greater value for the health system," said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. "When patients are engaged in treatment, monthly injectable buprenorphine can lessen reliance on emergency and inpatient care and ...